THE POSSIBLE ROLE OF SURVIVIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER
Keywords:Survivin, TCC, IHC
Background: Bladder cancer is third most common malignant tumors in both men and women in Iraq. Transitional cell carcinoma ( TCC) account for > 90% of bladder cancer. Survivin, family member of inhibitor of apoptosis (IAP) that play important role in both cell division and inhibit of apoptosis, Survivin express in vast majority of human cancer but not in normal adult tissues.
Objective: to evaluate the possible role of Survivin in patient of transitional cell carcinoma of bladder.
Materials and methods: formalin fixed, paraffin embedded tissue from (45) patients with transitional cell carcinoma of bladder from Al-Kadhimiya Teaching Hospital in Baghdad were included in this study. In addition, (16) apparently normal bladder biopsies were as a control groups. Tissue blocks were sectioned for detection of Survivin by Immunohistochemistry(IHC).
Results: Survivin was not expressed in normal bladder urothelium, and it was over expressed in 71.1% (32/45) of TCC patients (p=0.001) . Overexpression of survivin was associated with tumor grade (p=0.029), although there was no significant association (p=731), but there was different in reading between Survivin expression and muscle invasion.
Conclusion: Survivin is highly expression in TCC in compared with normal urothelium, and play key roles in survival of neoplastic cells by negative regulating apoptosis, and its correlated with poor prognosis in cancer.
Cassidy, A.; Wang, W.; Wu, X. and Lin, J. : Risk of urinary bladder cancer: a case-control analysis of industry and occupation. BMC Cancer; (2010) 9: 443.
Kadhim H.: Possible role of cell cycle regulatory proteins and nuclear factor-kB on the pathogenesis of transitional cell carcinoma of the bladder, (2004): PhD thesis, Medical college, Al-Nahrain university. Baghdad, Iraq.
Iraqi Cancer Registry (ICR) (2005).
Wei, Y.; Fan, T. and Miaomiao, Y.: Inhibitor of apoptosis proteins and apoptosis . Inhibitor of apoptosis. Acta Biochim Biophys Spinr. (2008); 40: 278-288.
Igney, F.; Krammer, P.: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer.(2002); 2: 277–88.
Liu, J. and Hongbo, l. : Survivin and hematologic malignancies, chin J Clinicians (electronic edition) (2011); 5(9): 2659-2662.
Rossi, D. and Gaidano, G.: Messengers of cell death: apoptotic signaling in health and disease. Haematological.(2003) ; 88: 212-218.
Skagias, L.; politi, E.; Karameris, A.; Sambaziotis, D.; Archondakis, A.; Ntinis, A.; Moreas, L.; Vasou, O.; Koutseline, H. and Patsouris, H.: Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining. cancer res. (2009); 29(10): 4163-7.
Altieri, D.: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene; (2003a) 22: 8581-8589.
Schultz, I.; Witjes, J.; Swinkels, D. and de Kok, J.: Bladder cancer diagnosis and recurrence prognosis: Comparison of markers with emphasis on Survivin, clinica chimica acta. (2006); 368: 20-32.
Altieri, D. Validating Survivin as a cancer therapeutic target, Nat. Rev. Cancer(2003b); 3: 46–54.
Li, F. and Ling, X.: Survivin Study: update of What is the next wave? J Cell Physiol. (2006); 208(3): 6–7.
Srinivasula, S. and Ashwell, J. : IAPs: what’s in a name? Mol. Cell(2008): 30, 123–135.
Riedl, S.; Renatus, M.; Schwarzenbacher, R.; Zhou, Q.; Sun, C.; Fesik, S.; Liddington, R. and Salvesen, G.: Structural basis for the inhibition of caspase-3 by XIAP. Cell(2001); 104: 791–800.
Dohi, T.; Okada, K.; Xia, F.; Wilford, C.; Samuel. T.; Welsh, K.; Marusawa, H.; Zou, H.; Armstrong, R.; Matsuzawa, S.; Salvesen, G.; Reed, J. and Altieri, D. : An IAP-IAP complex inhibits apoptosis. J Biol Chem (2004):; 279(33): 34087–34090.
Marusawa, H.; Matsuzawa, S.; Welsh, K.; Zou, H.; Armstrong, R.; Tamm, I. and Reed, J. :HBXIP functions as a cofactor of Survivin in apoptosis suppression. EMBO J. (2003); 22(11): 2729–2740.
Du, C.; Fang, M.; Li, L.; Li, Y. and Wang, X : Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000); 102: 33–42.
Verhagen, A.; Ekert, P.; Pakusch, M.; Silke, J.; Connolly, L.; Reid, G.; Moritz, R.; Simpson, R. and Vaux, D.:Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to an antagonizing IAP proteins. Cell (2000) ;102: 43–53.
Abrams, J.: An emerging blueprint for apoptosis in drosophila. Trends Cell Biol. (1999); 9: 435–440.
Shariat, S. ; Karakiewicz, P. ; Godoy, G. and Karam; J. :Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study. Clin. cancer research. (2009); 15(22): 7012-7019.
Kumar, V.; Abbas, A.; Fausto, N. and Aster, J. The lower urinary tract and male genital tract in: Robbins and Cotran Pathologic Basis of Disease.(8th ed.). Elsevier, Philadelphia, USA. (2010).
Jacobs, B.; Lee, C. and Montie, E: Bladder cancer in2010: How far have we come? CA Cancer j. (2010); 60(4): 244-272.
Margulis, V.; Lotan, Y. and Shariat, S.: Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J. Urol(2008); 26:59–65.
Kadhim H.: Transitional cell carcinoma of the Bladder Tumor grade correlation with tumor infiltration lymphocyte peripheral blood lymphocytes and oncofetal antigen. Msc. Thesis, medical college, Saddam University. Baghdad. Iraq. (1999).
Al Naib, K.: Efficacy of BCG intervesical instillation in Schistosomal and non Schistosomal bladder carcinoma : possible implications on tumor recurrence and on the immunological potency of Urothelial tumor cells and their infiltrating lymphocytes. Ph.D. Thesis ; Medical college, Al Nahrain University . Baghdad, Iraq. (1999).
Al-Qaysi, A. :Local staging of bladder carcinoma; endorectal MRI, histopathology, Immunohistochemistry and trace elements: correlative study. PhD thesis, Medical college, Al-Nahrain university. Baghdad, Iraq. (2002).
Swana, H.; Grossman, D.; Anthony, J.; Weiss, R. and Altieri, D. :Tumor content of the anti-apoptotic molecule Survivin and recurrence of bladder cancer. N Engl. J Med. (1999); 341: 452-453.
Zizhong, L.; Yuanxum, M. and Jinxing, W.: Expression of Survivin in Bladder carcinoma and its clinical significance, medical forum J. .(2007); abstract.
Nouraee, N.; Mowla, S. ; Ozhand, A.; Parvin, M.; Ziaee, S; Hatefi, N: Expression of Survivin and Its Spliced Variants in Bladder Tumors as a Potential Prognostic Marker, Urology j. .(2009); 6(2): 101-107.
KU, J. ; Kwak, C; Lee, H. ; Park, H.; Lee E. and Lee, S. : Expression of Survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder, The journal of Urology. (2004); 171: 631-635.